QSA founder Arman Eshaghi was a featured speaker at this week’s “Emerging Research & Trial Strategies for Progressive Multiple Sclerosis” webinar hosted by the New York Academy of Sciences. He overviewed new generation of machine learning models being developed at UCL to predict personalised prognosis of patients with multiple sclerosis. These models will be able to assist screening patients in clinical trials to help select those at higher risk of disability, and therefore, gauging treatment efficacy or trial recruitment based on patient’s future risk of disability. The utility of such models are to reduce the duration of clinical trials, specifically in progressive multiple sclerosis, to expedite drug development. The slides he covered can be found below.